Drug intelligence / Profile preview

durvalumab + saruparib

Development stage: Preclinical
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of durvalumab, a PD-L1 inhibitor immunotherapy, and saruparib, a selective PARP1 inhibitor. This combination targets both immune evasion mechanisms and DNA repair pathways in cancer cells. Durvalumab works by blocking the PD-L1 protein on cancer cells, preventing them from evading immune detection. Saruparib selectively inhibits PARP1 with minimal effect on PARP2, causing DNA damage to accumulate in cancer cells. This combination is being investigated for various advanced solid tumors, particularly those with specific genetic mutations.

Other names: Saruparib + durvalumab

Targets

PARP1 (Poly (adp-ribose) polymerase 1)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on durvalumab + saruparib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on durvalumab + saruparib.

Explore the full profile